Expression and clinical significance of c-met and HnRNP A2/B1 gene in non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2010.09.008
- VernacularTitle:c-met及HnRNP A2/B1 mRNA在非小细胞肺癌中的表达及其临床意义
- Author:
Lixin YU
;
Shengcai HOU
;
Hui LI
;
Bin HU
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Proto-oncogene proteins c-met;
HnRNP A2/B1 gene;
Mutation
- From:
Cancer Research and Clinic
2010;22(9):601-603,606
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the mRNA expression level of the hepatocyte growth factor receptor, c-met, and heterogeneous nuclear ribonucleoprotein, HnRNPA2/B1, in non-small cell lung cancer (NSCLC) patients and their relationships with invasion and metastasis of NSCLC. Methods The mRNA expressions of the c-met and HnRNP A2/B1 in postoperative samples of 46 patients with NSCLC and tissue samples of 30 patients with lung innocence disease as normal controls were detected by RT-PCR, and the efficacies of each marker and combining both of markers in the diagnosis of NSCLC were analyzed by Chi square test. Results The positive rates and relative expression quantity of c-met [65.2 % and (0.903±0.04)]and HnRNP A2/B1 [60.9 % and (0.162±0.04)] in NSCLC were significantly higher than those in control group [26.7 %, (0.205±0.06) and 20.0 %, (0.096±0.02), respectively] (P ＜0.05), and the positive rate of combining both was higher than that of single marker for NSCLC diagnosis(P ＜0.05) . The overexpression of two markers was also significantly correlated with the N stage and clinical stage, but not with age, gender and pathologic types. Conclusion The high expression of c-met and HnRNP A2/B1 in NSCLC may be of significance for the clinical stage. Combining test of two markers provides more sensitivity for NSCLC diagnosis. The expression change of two markers may involve in the carcinogenesis and development of NSCLC.
